Board and executive changes at Xceleron
This article was originally published in Scrip
Xceleron, a company which accelerates drug development using ultra-sensitive bioanalytical analyses, has appointed Dr David Roblin to its board in a non-executive capacity, and Dr Stuart Best senior director of operations. Dr Roblin most recently served as senior vice-president of R&D, research head and site director at Pfizer Global R&D. Dr Best joins Xceleron from Merck where he was head of bioanalysis.